Neurogene Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026The company raised cash to fund operations and research, which is crucial for a biotech company developing gene therapies.
This legal document describes the stock sale terms and risks, helping investors understand what they're buying.
This legal document describes the stock sale terms and risks, helping investors understand what they're buying.
Good clinical trial results suggest the company's medicine might work, which could lead to FDA approval and revenue.
Finishing the main trial is a major milestone; if approved, the company could sell this gene therapy soon.
Shareholders voted on company leadership and pay practices, which affect how the business is run and whether management acts fairly.
Quarterly earnings show whether the company is spending money wisely and moving toward profitability.
Stocky reads Neurogene Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Neurogene Inc.'s most recent tracked filing was a 8-K on 2 Jul 2026: Raises $134.8 million through stock and warrant offering.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.